Genetic markers of cisplatin-induced hearing loss in children.

about

Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.Ototoxicity monitoring in children treated with platinum chemotherapy.

P2860

Q36035287-F264600C-87E7-41F4-BF02-6BB1FF28B678 Q38654780-1C3A616E-768A-411D-8D6E-26F502F5EC94 Q39453840-5E4A0E41-3108-4F26-A608-B200D5DD01A7

P2860

Genetic markers of cisplatin-induced hearing loss in children.

Item

http://www.wikidata.org/entity/Q50354505

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Genetic markers of cisplatin-induced hearing loss in children.

@en

Genetic markers of cisplatin-induced hearing loss in children.

@nl

type

Item

label

Genetic markers of cisplatin-induced hearing loss in children.

@en

Genetic markers of cisplatin-induced hearing loss in children.

@nl

prefLabel

Genetic markers of cisplatin-induced hearing loss in children.

@en

Genetic markers of cisplatin-induced hearing loss in children.

@nl

P1476

Genetic markers of cisplatin-induced hearing loss in children.

@en

P2093

A P Bhavsar

http://www.w3.org/2001/XMLSchema#string

B Brooks

http://www.w3.org/2001/XMLSchema#string

H Visscher

http://www.w3.org/2001/XMLSchema#string

J W Lee

http://www.w3.org/2001/XMLSchema#string

K Pussegoda

http://www.w3.org/2001/XMLSchema#string

M R Hayden

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

Identification of cisplatin-regulated metabolic pathways in pluripotent stem cells

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.

Reproducibility: The risks of the replication drive.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

Challenges in interpreting the evidence for genetic predictors of ototoxicity.

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.

Application of principal component analysis to pharmacogenomic studies in Canada

P304

296-298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2014.92

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25141953

http://www.w3.org/2001/XMLSchema#string

Genetic markers of cisplatin-induced hearing loss in children.

about

P2860

P2860

Genetic markers of cisplatin-induced hearing loss in children.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698